Airway acidification initiates host defense abnormalities in cystic fibrosis mice

Viral S Shah1, David K Meyerholz2, Xiao Xiao Tang3

  • 1Department of Medicine, University of Iowa, Iowa City, IA 52242, USA. Department of Molecular Physiology and Biophysics, Pappajohn Biomedical Institute, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.

Science (New York, N.Y.)
|January 30, 2016
PubMed

Insights

Cystic fibrosis (CF) impairs airway defenses due to CFTR loss, but mice are spared. This study reveals that blocking H+/K+-ATPase (ATP12A) in humans and pigs restores defenses, identifying ATP12A as a therapeutic target for CF.

Area of Science:

  • Physiology
  • Molecular Biology
  • Respiratory Medicine

Background:

  • Cystic fibrosis (CF) is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
  • CFTR dysfunction impairs respiratory host defenses, leading to airway infections in humans and pigs, but not in mice.

Purpose of the Study:

  • To investigate the underlying mechanisms explaining why CF mice are resistant to infection despite CFTR mutations.
  • To identify potential therapeutic targets for CF by understanding species-specific differences in airway physiology.

Main Methods:

  • Comparative analysis of airway surface liquid pH and ion transport in humans, pigs, and mice with and without CFTR.
  • Inhibition of H+/K+-ATPase (ATP12A) in human and pig airway tissues.
  • Expression of ATP12A in CF mouse airway epithelia.

Main Results:

  • CFTR normally secretes bicarbonate into airway surface liquid across species.
  • In CF humans and pigs, lack of CFTR leads to unchecked H+ secretion by ATP12A, acidifying airway surface liquid and impairing defenses.
  • Mouse airways have minimal ATP12A activity, resulting in similar airway surface liquid pH in CF and non-CF mice, thus protecting them from infection.

Conclusions:

  • Species-specific differences in ATP12A activity explain the absence of infection in CF mice.
  • Inhibiting ATP12A in human and pig airways can reverse CF-related host defense abnormalities.
  • ATP12A represents a promising therapeutic target for treating cystic fibrosis.